A Study of BCD-135 in Patients With Advanced Solid Tumors

• ClinicalTrials.gov Identifier: NCT03464032
• Recruitment Status: Unknown
• First Posted: March 13, 2018
• Last Update Posted: March 13, 2018
• Sponsor: Biocad
• Information provided by (Responsible Party): Biocad

Study Description

Brief Summary:

A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-135 (JSC BIOCAD, Russia) in Patients with Advanced Solid Tumors

Condition or disease	Intervention/treatment	Phase
Melanoma; NSCLC; Renal Cell Carcinoma; Bladder Cancer	Drug: BCD-135	Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 30 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-135 (JSC BIOCAD, Russia) in Patients With Advanced Solid Tumors
• Actual Study Start Date: October 31, 2017
• Estimated Primary Completion Date: May 31, 2018
• Estimated Study Completion Date: October 31, 2018

Arms and Interventions

Arm	Intervention/treatment
Experimental: BCD-135; Dose-escalation Arm (0.4, 1, 3, 10, 20 mg/kg)	Drug: BCD-135; Monoclonal anti-PD-L1 antibody

Outcome Measures

Primary Outcome Measures :

1. DCR [ Time Frame: 85 days ]
   Disease control rate (CR+PR+SD). Pilot efficacy assessment is not the primary objective of this study and will be conducted by surrogate endpoints describing the direct antitumor effect of the drug.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Patient provides a written informed consent and is able to follow the requirements of the Protocol;
2. Age ≥ 18 years

3. Histologically confirmed cancer (well-documented test results; preferably, block specimens available):

   • Unresectable (stage III/IV) or metastatic (stage IV) melanoma (the drug will be used as the first or subsequent therapy lines);
   • Locally advanced or metastatic EGFR/ALK wt NSCLC (squamous cell carcinoma/adenocarcinoma), progressive after the first-line therapy with platinum-based CT or EGFR/ALK wt NSCLC progressive after the first-line therapy with EGFR/ALK inhibitors (the drug will be used as a second therapy line);
   • Metastatic clear cell renal carcinoma, progressive after at least the first-line therapy (the drug will be used as a second or third therapy lines);
   • Locally advanced or metastatic bladder cancer progressive on/after therapy with platinum-based CT (the drug will be used as a second therapy line);
4. ECOG score of 0 to 1;
5. Presence of blocks for histological examination and/or patient's agreement to conduct a biopsy of an accessible lesions to obtain a histological material for examination of PD-L1 status
6. Measurable disease (at least one lesion) according to RECISTv.1.1;
7. Resolved toxicity events from the previous therapy or adverse consequences of surgical interventions to ≤ grade 1 CTCAE v. 4.03, except for chronic/irreversible adverse events not affecting the safety of the study therapy (e.g. alopecia);
8. No severe pathology of organs or systems;
9. Life expectancy of at least 12 weeks from the screening;
10. Patients of childbearing potential enrolled in the study must agree to use reliable contraception methods throughout the study period, beginning 2 weeks before the inclusion in the study and up to 8 weeks after the last dose of BCD-100.

Exclusion Criteria:

1. Severe concomitant illnesses or life-threatening consequences (including pleural/pericardial/peritoneal effusion that requires medical intervention, pulmonary lymphangitis, or involvement of >50% renal parenchyma);
2. Brain metastases, progressive or associated with clinical symptoms (e.g. cerebral edema or spinal cord compression). Exclusions: metastases that do not progress and do not require steroids and/or anticonvulsants within at least 4 weeks before randomization;
3. Severe cardiovascular disorders within 6 months before screening;
4. Autoimmune diseases;
5. Conditions requiring steroids or any other immunosuppressants;
6. Blood disorders: ANC ≤1,500/mm3; platelets ≤100,000/mm3; or Hb ≤90 g/L;
7. Renal function impairment: creatinine ≥1.5 × ULN;
8. Hepatic function impairment: bilirubin ≥1.5 × ULN; AST and ALT ≥2.5 × ULN (5 × ULN for patients with liver metastases), AlkPh ≥ 5 × ULN;
9. LDH level >2 ULN;
10. Prior anticancer treatment within 28 days before starting the study drug (surgery, radiation therapy, targeted therapy, immunotherapy, vaccine treatment or chemotherapy);

11. More than

    • 2 therapy lines of unresectable/metastatic melanoma,
    • 1 therapy line of metastatic NSCLC,
    • 2 therapy lines of metastatic RCC;
    • 1 therapy line of metastatic BC;
12. Prior treatment with anti-PD1/PDL1 agents or CTLA4 inhibitors;
13. Concurrent malignancy except for radically resected cervical carcinoma in situ or radically resected basal cell/squamous cell carcinoma;
14. Conditions limiting patient's ability to follow the Protocol requirements (dementia, neurological or psychiatric disorders, drug or alcohol abuse, etc.);
15. Simultaneous participation in any other clinical trial; participation in other clinical trials within 28 days before inclusion in the present study; previous participation in the present study.
16. Acute infections or active chronic infections;
17. Documented HIV infection;
18. Positive screening results for Hbs-antigen, hepatitis B core antibodies (anti-HBc Ab) and/or hepatitis C antibodies;
19. Positive results of microprecipitation reaction together with positive TPHA assay results at the screening;
20. Body weight > 100 kg.
21. Intravenous administration of the drug is impossible;
22. Intravenous administration of contrast agents is impossible;
23. Hypersensitivity to any component of BCD-100.
24. Known history of hypersensitivity to monoclonal antibodies;
25. Pregnancy or breastfeeding;

Contacts and Locations

Contacts

Contact: Mariia Shustova, MD; +7 (812) 380 49 33 ext 651; shustova@biocad.ru

Locations

Russian Federation

LLC BioEk; Recruiting

Saint-Petersburg, Russian Federation

Contact: Svetlana Odintsova, MD +78129452232

Sponsors and Collaborators

Biocad

Investigators

• Principal Investigator: Svetlana Odintsova, MD; LLC BioEk

More Information

• Responsible Party: Biocad
• ClinicalTrials.gov Identifier: NCT03464032
• Other Study ID Numbers: BCD-135-1
• First Posted: March 13, 2018
• Last Update Posted: March 13, 2018
• Last Verified: March 2018

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Carcinoma, Renal Cell; Neoplasms by Histologic Type; Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Urologic Diseases; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Kidney Neoplasms; Kidney Diseases